Shots:
- Fresenius Kabi launched Conexxence and Bomyntra, biosimilar of Prolia & Xgeva (denosumab) for all indications of the reference products across the US
- Conexxence (denosumab-bnht) 60 mg/mL, available in PFS, is approved for adults at high risk of fractures, including those with osteoporosis, pts. on cancer treatments affecting bone density, or long-term glucocorticoids
- Bomyntra (denosumab-bnht) 120 mg/1.7 mL, available in a vial and a PFS, is approved to prevent skeletal-related events in patients with multiple myeloma or bone metastases from solid tumors
Ref: BusinessWire | Image: Fresenius Kabi | Press Release
Related News:- Fresenius kabi Secures the CHMP’s Positive Opinion for Bomyntra & Conexxence (Biosimilar, Prolia and Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
